In a paper published in Alzheimer’s and Dementia, a team of researchers called for more prospective studies that will look into the impact COVID-19 has on brain functioning, given the disease has been frequently associated with neurologic symptoms such as seizures and psychosis.

Why pharma has been slow to engage its customers, and what we can do about it.

ZUG, Switzerland, Aug. 13, 2015 /PRNewswire/ — Feedback gathered from 97 neurologists in June reveals that growing comfort with oral disease-modifying agents (DMAs) as well as multiple years of patient experience is driving neurologists to leave the injectables behind. While experience benefits oral agents moving forward in the treatment armamentarium, it is not the same story for […]